NEW YORK, Dec. 4, 2014 /PRNewswire/ --

Avanir Pharmaceuticals, Inc.

Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of Avanir Pharmaceuticals, Inc. ("AVNR") to Otsuka Pharmaceutical Co., Ltd. in an all-cash transaction valued at approximately $3.5 billion or $17 per share.  

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Carbonite, Inc.

Lifshitz & Miller  announces investigation into possible breaches of fiduciary duties in connection with the unsolicited proposal from J2 Global, Inc. to acquire Carbonite, Inc. ("CARB") for $15.00 per share in cash.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Casey's General Stores, Inc.

Lifshitz & Miller  announces investigation into possible breaches of fiduciary duties by the board of Casey's General Stores, Inc. ("CASY").  Specifically, on November 24, 2014, CASY discovered a $30 million error in its income taxes related to tax credits on ethanol that is blended into gasoline and will revise its financial statements.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Nymox Pharmaceutical Corporation  

Lifshitz & Miller  announces investigation into possible breaches of fiduciary duties by the board of Nymox Pharmaceutical Corporation ("NYMX").  Specifically, on November 3, 2014, NYMX announced that two phase 3 studies of its prostate enlargement treatment failed to produce the desired results.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Puma Biotechnology Inc.

Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the board of Puma Biotechnology Inc. ("PBYI").  Specifically, on December 2, 2014, PBYI announced its PB272 drug application will be delayed from first half 2015 to first quarter 2016 and that the application will seek to approve the drug to treat early-stage breast cancer instead of metastatic breast cancer.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

RealD Inc.

Lifshitz & Miller  announces an investigation into possible breaches of fiduciary duties by the board of RealD Inc. ("RLD").  Specifically, on November 3, 2014, RLD announced that it rejected an unsolicited $12-a-share takeover bid from Starboard Value LP.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Spansion, Inc.

Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of Spansion, Inc. ("CODE") to Cypress Semiconductor Corp. in an all-stock transaction valued at approximately $4 billion.  

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

ATTORNEY ADVERTISING. © 2014 Lifshitz & Miller.  The law firm responsible for this advertisement is Lifshitz & Miller, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: (516) 493-9780.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:
Joshua M. Lifshitz, Esq.
Lifshitz & Miller
Phone:  516-493-9780
Facsimile: 516-280-7376
Email: info@jlclasslaw.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lifshitz--miller-law-firm-announces-investigation-of-avanir-pharmaceuticals-inc-carbonite-inc-caseys-general-stores-inc-nymox-pharmaceutical-corporation-puma-biotechnology-inc-reald-inc-and-spansion-inc-300005090.html

SOURCE Lifshitz & Miller Law Firm

Copyright 2014 PR Newswire

Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Nymox Pharmaceutical Charts.
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Nymox Pharmaceutical Charts.